Generic Name and Formulations:
Liothyronine sodium 5mcg, 25mcg, 50mcg; tabs.
Indications for CYTOMEL:
Hypothyroidism: initially 25mcg daily; may increase by up to 25mcg every 1–2 weeks; usual maintenance 25–75mcg daily. Myxedema, simple goiter: initially 5mcg daily; may increase by 5–10mcg daily every 1–2 weeks to 25mcg daily, then may increase by 5–25mcg every 1–2 weeks (myxedema) or by 12.5 or 25mcg daily every 1–2 weeks (simple goiter). Maintenance: myxedema: 50–100mcg/day; simple goiter: 75mcg/day.
Initially 5mcg daily; may increase by 5mcg daily every 3–4 days. Cretinism: maintenance dose: <1yr: 20mcg/day. 1–3 yrs: 50mcg/day. >3yrs: as adult.
Initially 5mcg daily; may increase by 5mcg every 1–2 weeks.
Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis.
Larger doses particularly when given concomitantly with sympathomimetic amines for anorectic effects may produce serious or life-threatening toxicity.
Not for treatment of obesity or infertility (unless with hypothyroidism). Cardiovascular disease, angina, elderly: use lower initial dose. Adrenocortical insufficiency. Diabetes. Monitor for craniosynostosis in infants. Pregnancy (Cat.A). Nursing mothers.
Monitor oral anticoagulants, hypoglycemics, digoxin. Estrogens affect thyroid function tests. Monitor for hypertension with ketamine. Toxicity with larger doses of sympathomimetics (eg, anorectics).
Hyperthyroidism, transient hair loss in children.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness